Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Hemogenyx Pharma Plc (HEMO)

  Print      Mail a friend

Thursday 07 December, 2017

Hemogenyx Pharma Plc

AGM Statement

RNS Number : 6267Y
Hemogenyx Pharmaceuticals PLC
07 December 2017


This announcement contains inside information which, prior to its disclosure, was inside information for the purposes of the Market Abuse Regulation (Article 7 of Regulation (EU) No 596/2014.


Hemogenyx Pharmaceuticals Plc

("Hemogenyx" or the "Company")


AGM Statement


Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, will hold its Annual General Meeting today at 10:00am at the offices of Charles Russell Speechlys LLP, 5 Fleet Place, London EC4M 7RD.  


Ahead of the formal business of the AGM, the Board will provide the following strategic update on its activities, technology and products following its successful IPO and Admission to the main market of the London Stock Exchange (LSE) on 5 October 2017:


Laboratory activities are progressing well and to plan, with capacity expanded and the Company's modest scientific recruitment programme almost complete. Activities are focused on working with LakePharma Inc. and Oxford University, its recently announced collaborator, to help progress two distinct but complementary novel proprietary therapies, CDX (a novel bispecific antibody) and HuPHEC (a novel cell therapy), which aim to change the way in which bone marrow/hematopoietic stem cell transplants (BMT/HSCT) are performed and strongly improve their efficacy.


The appointment of LakePharma provides a strategic partner to help accelerate development of the Company's CDX bispecific antibody (an immunotherapy-class treatment) for patient 'conditioning', the first step required in preparing patients for a BMT. The Company aims to replace current toxic conditioning modalities, which include radiation and chemotherapy, thereby increasing the number of candidate patients for BMT and allowing a greater proportion of these to be successfully conditioned for the subsequent bone marrow transplant. LakePharma, the largest US-based biologics contract research organisation, brings integrated antibody engineering and bioproduction expertise to allow Hemogenyx to advance its CDX product through the necessary preclinical stages to potentially be ready to enter the clinic within 16 months. To date, work is progressing successfully toward the Company's immediate goal of submitting an IND application to the US Food and Drug Administration. 


As announced in October, Hemogenyx has engaged LakePharma for the development and manufacture of CDX antibodies for Hemogenyx's conditioning product, a major step in the pre-clinical development of this product using the expertise and validated technology of LakePharma, the largest US-based biologics contract research organisation.


The collaboration with the University of Oxford and Professor Jagdeep Nanchahal's team at the Kennedy Institute of Rheumatology aims to examine the action of certain biological molecules on stimulating transplanted blood stem cells to transition - faster and more effectively - from dormant to activated state to produce healthy blood cells. The Company anticipates that the resulting increase in the number of activated blood stem cells will result in the accelerated engraftment of hematopoietic stem cells when transplanted in a BMT. This work could lead to additional uses of the Company's HuPHEC product. HuPHECs, or Human Post-natal Hemogenic Endothelial Cells, are Hemogenyx's proprietary source of blood stem cells that are able to generate cancer-free, patient-matched blood stem cells and represent the basis for the Company's novel cell therapy. A successful outcome of the work with Oxford University has the potential to significantly improve the efficiency and safety of future bone marrow transplants.


In addition, Hemogenyx has expanded its material transfer agreement with a major US research university, under which Hemogenyx has secured a reliable high-quality supply of human tissues for the development of both its CDX bispecific antibody product and its HuPHEC cell therapy product.


The Board of Directors are evaluating additional collaborations with a range of potential academic and corporate partners, and hope to be in a position to update shareholders on progress in due course.


In summary, the Directors believe that the Company is well-advanced on the planned development steps that were announced on its Admission and are looking forward to the next 12 months with great confidence and high expectations.


Commenting on the Company's progress thus far, Dr. Vladislav Sandler, CEO of Hemogenyx, said: "We believe the products we are developing should greatly reduce the dangers of patient conditioning procedures and create a new form of blood stem cell transplantation which, if successful, would significantly enhance the long-term success of bone marrow transplants. The appointment of LakePharma and collaboration with Oxford University represent significant steps towards our strategic goal of applying novel technologies to transform the lives of bone marrow transplant patients. We look forward to keeping shareholders fully abreast of developments as they occur."




Hemogenyx Pharmaceuticals Limited

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

Via Walbrook PR

Dr Robin Campbell, Chairman

Optiva Securities Ltd

Tel: +44 (0)20 3137 1902

Christian Dennis 

Shard Capital Partners LLP

Tel: +44 (0)20 7186 9950

Damon Heath, Erik Woolgar

Peterhouse Corporate Finance Limited

Tel: +44 (0)20 7469 0930

Lucy Williams/Duncan Vasey

Walbrook PR

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus

Mob: +44 (0)7980 541 893


About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit


This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t